amino.flo Facebook ad: “If you’re running CJC-1295, there’s a decent chance…”

Ran for 47 days, from August 2 to September 18, 2026, the last day Crush saw it.
Run by amino.flo on Instagram. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1655948345470568
- Platforms
- Relaunches
- 0
Ad text
If you’re running CJC-1295, there’s a decent chance you don’t actually know what’s in your vial — because two completely different molecules get sold under the same name, and they behave nothing alike. ✨ What it is: a stacked pair of growth-hormone secretagogues. CJC-1295 is a long-acting GHRH analog (tells the pituitary to make more GH); Ipamorelin is a selective ghrelin-receptor agonist that triggers clean GH pulses. Together they raise GH and downstream IGF-1. The mislabel problem: “CJC-1295” is sold in two forms — with DAC and without DAC (the no-DAC version is really mod-GRF 1-29). They are NOT interchangeable: → Teichman et al., J Clin Endocrinol Metab (2006): CJC-1295 with DAC has a half-life of 5.8–8.1 days, raising GH 2–10x for 6+ days and IGF-1 1.5–3x for 9–11 days from a single dose. → Ionescu & Frohman, J Clin Endocrinol Metab (2006): CJC-1295 without DAC lasts hours, not days — it sharpens individual GH pulses but doesn’t produce that multi-day elevation. The DAC (Drug Affinity Complex) binds to albumin so the molecule resists breakdown — that’s the entire reason for the days-vs-hours gap. A vial simply labeled “CJC-1295” tells you almost nothing about which one you have or how to time it. The Ipamorelin footnote: Raun et al., Eur J Endocrinol (1998) — the foundational (animal) paper — showed Ipamorelin releases GH selectively without spiking cortisol or ACTH, which is why it’s the preferred pairing. But that’s a rodent characterization; human efficacy data for Ipamorelin is essentially absent. The honest reframe: these are research compounds, not approved drugs. A handful of small, short human PK studies confirm the hormones move — there are no long-term human trials showing muscle gain, fat loss, or safety. So even setting aside the labeling chaos, the human outcome data just isn’t there yet. Bottom line: if you can’t tell whether your vial is with-DAC or without-DAC, you can’t dose or time it correctly — and you’re guessing on a compound whose human evidence is thin to begin with. Educational content only. Not medical advice. Save this before your next order. Comment FLO for an invite to our research Discord










